Literature DB >> 16400354

CccDNA persistence during natural evolution of chronic VHB infection.

Florin Alexandru Caruntu1, Violeta Molagic.   

Abstract

HBV infection remains a public health issue. CccDNA-HBV is a unique, intermediate replicative episome, responsible for persistence of infection in hepatocytes. The clearance of cccDNA may be explained by cellular death. CccDNA detection in chronic infected human livers may represent an important marker in monitoring antiviral therapy. Short term therapy is followed by viral rebound in the majority of chronic HBV hepatitis patients. Based on mathematical models, it is considered that the period needed to achieve a complete intrahepatic cccDNA clearance is 14.5 years.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16400354

Source DB:  PubMed          Journal:  Rom J Gastroenterol        ISSN: 1221-4167


  12 in total

Review 1.  The underlying mechanisms for the "simultaneous HBsAg and anti-HBs serological profile".

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-12       Impact factor: 3.267

Review 2.  Molecular mechanisms underlying HBsAg negativity in occult HBV infection.

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-24       Impact factor: 3.267

3.  Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment.

Authors:  Hong Shi; Lu Lu; Ning-Ping Zhang; Shun-Cai Zhang; Xi-Zhong Shen
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

4.  DNA double-strand breaks, potential targets for HBV integration.

Authors:  Xiaowen Hu; Jusheng Lin; Qionghui Xie; Jinghua Ren; Ying Chang; Wenjie Wu; Yujia Xia
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-06-17

5.  DNA Repair Factor Poly(ADP-Ribose) Polymerase 1 Is a Proviral Factor in Hepatitis B Virus Covalently Closed Circular DNA Formation.

Authors:  Yingshan Chen; Yongxuan Yao; Kaitao Zhao; Canyu Liu; Yifei Yuan; Hao Sun; Dan Huang; Yi Zheng; Yuan Zhou; Jizheng Chen; Yun Wang; Chunchen Wu; Bixiang Zhang; Yujuan Guan; Feng Li; Rongjuan Pei; Xinwen Chen
Journal:  J Virol       Date:  2022-06-07       Impact factor: 6.549

6.  Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.

Authors:  Scott Bowden; Stephen Locarnini; Ting-Tsung Chang; You-Chen Chao; Kwang-Hyub Han; Robert G Gish; Robert A de Man; Miao Yu; Cyril Llamoso; Hong Tang
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

7.  Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication.

Authors:  Jie Wang; Zhong-Wei Xu; Shuang Liu; Rui-Yang Zhang; Shan-Long Ding; Xiao-Meng Xie; Lu Long; Xiang-Mei Chen; Hui Zhuang; Feng-Min Lu
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

Review 8.  Atypical serological profiles in hepatitis B virus infection.

Authors:  Robério A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-29       Impact factor: 3.267

9.  Development of magnetic capture hybridization and quantitative polymerase chain reaction for hepatitis B virus covalently closed circular DNA.

Authors:  Yongcan Guo; Shangchun Sheng; Bin Nie; Zhiguang Tu
Journal:  Hepat Mon       Date:  2015-01-05       Impact factor: 0.660

10.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo.

Authors:  Su-Ru Lin; Hung-Chih Yang; Yi-Ting Kuo; Chun-Jen Liu; Ta-Yu Yang; Ku-Chun Sung; You-Yu Lin; Hurng-Yi Wang; Chih-Chiang Wang; Yueh-Chi Shen; Fang-Yi Wu; Jia-Horng Kao; Ding-Shinn Chen; Pei-Jer Chen
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-19       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.